Plasma Biomarkers P-DAC, V1
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 240
Summary
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will involve two cohort groups, all patients involved will have PDAC. Cohort A: Target is 80 resectable PDAC patients who will receive standard treatment of chemotherapy +/- radiotherapy Cohort B: Cohort B1 = Target is 80 unresectable locally advanced PDAC patients who will receive standa...
This study will involve two cohort groups, all patients involved will have PDAC. Cohort A: Target is 80 resectable PDAC patients who will receive standard treatment of chemotherapy +/- radiotherapy Cohort B: Cohort B1 = Target is 80 unresectable locally advanced PDAC patients who will receive standard treatment of chemotherapy +/- radiotherapy. Cohort B2 = Target is metastatic PDAC patients who will receive standard treatment of chemotherapy +/- radiotherapy. Control patients: Target is 50, with acute pancreatitis admitted to hospital for observation/treatment. Blood samples will be taken at the following time points: prior to resection, whenever feasible for cohort A prior to CT, for both cohort A and B during CT, for both cohort A and B follow-up, approximately every 3 to 6 months for two years for cohort A
Tracking Information
- NCT #
- NCT02050997
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon